Evidence map›Paper›PMID 33822824›Full record

ArticlePloS one2021

HIV-associated nephropathy: Protocol and rationale for an exploratory genotype-phenotype study in a sub-Saharan African population.

Aminu Abba Yusuf, Baba Maiyaki Musa, Najibah Aliyu Galadanci, Musa Babashani, Aminu Zakari Mohammed, Donna J Ingles, Agnes B Fogo, C William Wester, Muktar Hassan Aliyu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Aminu Abba YusufDepartment of Haematology and Blood Transfusion, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria.ORCID 0000-0002-6132-9534
Baba Maiyaki MusaDepartment of Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria.
Najibah Aliyu GaladanciDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Musa BabashaniDepartment of Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria.
Aminu Zakari MohammedDepartment of Histopathology, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria.
Donna J InglesVanderbilt Institute of Global Health (VIGH), Nashville, Tennessee, United States of America.
Agnes B FogoDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
C William WesterVanderbilt Institute of Global Health (VIGH), Nashville, Tennessee, United States of America.
Muktar Hassan AliyuVanderbilt Institute of Global Health (VIGH), Nashville, Tennessee, United States of America.
Aminu Kano Teaching Hospital · NGVanderbilt Health · USAfrica Center · USUniversity of Alabama at Birmingham · USVanderbilt University Medical Center · US

Funding

Vanderbilt-Emory-Cornell-Duke Global Health Fellowship Consortium-Expanding Diversity for Global Equity (EDGE)D43TW009337 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, HEIMBURGER, DOUGLAS CORBETT · 2017 to 2021
$6.3M
Optimal Management of HIV Infected Adults at Risk for Kidney Disease in NigeriaU01DK112271 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, WESTER, C. WILLIAM · 2017 to 2022
$3.2M
Vanderbilt-Nigeria Building Research Capacity in HIV and Non-communicable Diseases (NCDs) (V-BRCH) 2D43TW011544 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Aishatu Adamu, Muktar Hassan Aliyu · 2020 to 2026
$2.1M
FIC NIH HHS D43 TW009337FIC NIH HHS D43 TW011544NIDDK NIH HHS U01 DK112271
6 · The paper itself

Abstract

backgroundHIV-positive persons of African descent are disproportionately affected by chronic kidney disease (CKD). Deterioration to end-stage kidney disease (ESKD) also occurs in this population at a higher frequency. There remains a lot to learn about the genetic susceptibility to CKD in HIV positive patients, and the pathophysiology of progression to ESKD.

objectivesWe will conduct an exploratory genotype-phenotype study in HIV-positive persons with CKD in Aminu Kano Teaching Hospital, Nigeria, to determine blood-based differential gene expression biomarkers in different kidney risk groups according to the KDIGO 2012 criteria.

methodsWe will consecutively screen 150 HIV-positive adults (≥18 years of age) attending the HIV clinic of Aminu Kano Teaching Hospital, Kano, Nigeria, for CKD based on proteinuria and elevation of estimated glomerular filtration rate. Among these, two separate groups of 16 eligible participants each (n = 32) will be selected in the four (4) KDIGO 2012 kidney risk categories. The groups will be matched for age, sex, viral suppression level and antiretroviral (ARV) regimen. In the first group (n = 16), we will determine differential gene expression markers in peripheral blood mononuclear cells using mRNA-sequencing (RNA-Seq). We will validate the differential expression markers in the second group (n = 16) using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Using a systems-based approach, we will construct, visualize and analyze gene-gene interaction networks to determine the potential biological roles of identified differential expression markers based on published literature and publicly available databases.

resultsOur exploratory study will provide valuable information on the potential roles of differential expression biomarkers in the pathophysiology of HIV-associated kidney disease by identifying novel biomarkers in different risk categories of CKD in a sub-Saharan African population. The results of this study will provide the basis for population-based genome-wide association studies to guide future personalized medicine approaches.

conclusionValidated biomarkers can be potential targets for the development of stage-specific therapeutic interventions, an essential paradigm in precision medicine.

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseasePolymorphism, Single NucleotideAfrica South of the SaharaAIDS-Associated NephropathyBiomarkersBlack PeopleDisease ProgressionGlomerular Filtration RateHumansLeukocytes, MononuclearRNA-SeqBiomarkers

Identifiers

PMID33822824
PMCPMC8023480
OpenAlexW3150552018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.